SPIRIVA RESPIMAT

Peak

tiotropium bromide inhalation spray

NDAINHALATIONSPRAY
Approved
Sep 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4

Mechanism of Action

long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors, M 1 to M 5 . In the airways, it exhibits pharmacological effects through inhibition of M 3 -receptors at the smooth muscle leading to…

Clinical Trials (4)

NCT03692676N/ACompleted

Characteristics of Pts Initiating Spiriva Respimat in Asthma

Started Mar 2019
116,133 enrolled
Asthma
NCT03188120N/ACompleted

Specific Use-Result of Spiriva Respimat® in Asthmatics

Started Jul 2017
193 enrolled
Asthma
NCT02489981N/ACompleted

Specific Use-result Surveillance of Spiriva Respimat in Asthmatics

Started Jun 2015
359 enrolled
Asthma
NCT00699699N/ACompleted

Observational Non-Interventional Study With Spiriva Respimat in COPD Patients

Started Jun 2008
1,280 enrolled
Pulmonary Disease, Chronic Obstructive